查詢結果分析
相關文獻
- β-阻斷劑劑量對心衰竭預後之探討
- 綜觀國外心衰竭之臨床試驗
- High Output Heart Failure due to a Common Iliac Arteriovenous Fistula Associated with Angina Pectoris--a Case Report and Review of Literature
- Evaluation of Myocardial Dysfunction by Radionuclide Ventricular Ejection Fraction in Heart Failure Patients after Prosthetic Valve Replacement
- 兒童鬱血性心衰竭之病態生理及藥物治療
- 心房粘液瘤--臨床分析與文獻回顧
- Spironolactone對鬱血性心衰竭治療的最新進展
- Recurrent Gastrointestinal Bleeding and High Output Cardiac Failure Caused by Hereditary Hemorrhagic Telangiectasia
- Hypocalcemic Dilated Cardiomyopathy: A Case Report
- 內皮素與心衰竭
頁籤選單縮合
題 名 | β-阻斷劑劑量對心衰竭預後之探討=The Efficiency of Beta-Blocker Doses on Clinical Outcomes in Patients with Heart Failure |
---|---|
作 者 | 陳佳南; 賴輝雄; 林慧娟; | 書刊名 | 藥學雜誌 |
卷 期 | 31:3=124 2015.09[民104.09] |
頁 次 | 頁50-55 |
分類號 | 418.22 |
關鍵詞 | 心衰竭; β-阻斷劑; 目標劑量; Heart failure; β-blocker; Target dose; |
語 文 | 中文(Chinese) |
中文摘要 | β-阻斷劑在心衰竭的治療主要改善左心室射出分率,可減低住院率和死亡率。 臨床指引建議β-阻斷劑以低劑量開始使用,逐漸增加劑量來達到目標劑量。然而β- 阻斷劑的劑量與藥物不良反應發生有相關性,因此臨床上,β-阻斷劑的劑量多未達 建議劑量。此外,考量β-阻斷劑劑量的調整,當劑量低於目標劑量時,但心跳速率 下降已達最大減幅,是否需再增加β-阻斷劑的劑量至目標劑量,和若心跳速率下降 低幅度偏小,是否仍需將β-阻斷劑的劑量提高大於目標劑量,仍缺少臨床佐證。本 文以實證方法探討臨床上使用β-阻斷劑的劑量與降低心跳速率在心衰竭患者治療療 效的相關性和效益,及副作用發生的關聯性,並以實證藥學來提供臨床應用。 |
英文摘要 | β-blockers improve left ventricular ejection fraction and reduce hospitalization or mortality of patients with heart failure. Clinical guidelines suggest that patients with heart failure should take β-blockers doses from the low doses to the target doses gradually. However, since doses of β-blocker are related to their adverse effects, patients in clinical treatment usually take the under-target doses. Furthermore, two assumptions of this study need to be examined: first, if patients take the under-target doses and the heart rate reduces significantly, the physician should consider to increase the β-blocker doses to the target doses; second, if patients take the target doses and the heart rate reduces insignificantly, the physician should consider to increase the doses over the target doses. The above two assumptions still lack any clinical trial to validate. Therefore, this article conduct an evidence-based practice on efficacy and adverse effects with the β-blocker doses in patients with heart failure and offer better pharmaceutical care. |
本系統中英文摘要資訊取自各篇刊載內容。